ONI BioPharma Inc. Commences Market Launch of Unique Oral Probiotic Product
September 18 2008 - 4:42PM
Marketwired
ONI BioPharma Inc. (AMEX: ONI) announced today that it is
commencing the marketing launch of its unique oral care group of
probiotics, known collectively as ProBiora3(TM). This extraordinary
technology is the result of over 30 years of scientific and
clinical research. ProBiora3 is an integrated oral care product
that contains three natural, human-derived, oral probiotic bacteria
designed to promote healthy teeth and gums, as well as whiten teeth
and freshen breath.
ProBiora3 will be distributed through a wide array of mass
marketing channels beginning with a group of products manufactured
by and for ONI under the name Evora. The first product, a wholly
natural mint flavored lozenge, will be known as EvoraPlus(TM) and
will address adult oral health. Following shortly thereafter, the
Company will market modified formulations that address the oral
health needs of children and the fast-growing companion pet
market.
All of the ProBiora3 products will be marketed under the
generally recognized as safe (GRAS) provision of the U.S. FDA
regulations. One of the elements of GRAS status is that it limits
the type of claims that ONI can make with respect to this group.
GRAS status goods account for billions of dollars in sales of
beneficial products. In sales previews, mass retailers have
indicated a desire to purchase the product in substantial
quantities for the final quarter of 2008 as well as in larger
quantities for the 1st quarter of 2009.
ONI has hired Gerald David, a widely recognized expert in
nutraceutical sales, along with other key staff members to manage
the sales and marketing of ProBiora3. Mr. David, who will operate
out of a new sales office located in Tampa, FL, has planned a
television, print media and internet information and sales
campaign, which has already begun in the United States. EvoraPlus
will be offered on a number of large retail sales sites. ONI is
arranging for a credit facility to finance these efforts. Retailers
can expect initial deliveries in October.
ONI believes that the ProBiora3 group of products will join
other successful probiotics which have long been sold throughout
the world, and more recently in the United States. ProBiora3 will
be the first probiotic that address all of the major oral health
concerns.
The Company's President and CEO, Stanley B. Stein, stated that,
"ProBiora3 represents ONI's long-term commitment to commercialize
its extraordinary scientific platforms, and I expect that further
announcements about new products, projects, initiatives, and
realized sales will be forthcoming with regularity."
About ONI BioPharma Inc.
ONI BioPharma Inc. is a biopharmaceutical company with a
pipeline of unique proprietary technologies, some of which are
being commercialized. The Company also has a number of products in
discovery, preclinical and clinical development, with a
concentration in the main therapeutic area of infectious diseases,
diagnostics, and oral health. The Company has developed platform
technologies with respect to its products, thereby creating a
pipeline of future products, which the Company expects to
develop.
Safe Harbor Statement: Under the Private Securities Litigation
Reform Act of 1995: This release includes forward-looking
statements that reflect ONI BioPharma's current views with respect
to future events and financial performance. These forward-looking
statements are based on management's beliefs and assumptions and
information currently available. The words "believe," "expect,"
"anticipate," "intend," "estimate," "project" and similar
expressions that do not relate solely to historical matters
identify forward-looking statements. Investors should be cautious
in relying on forward-looking statements because they are subject
to a variety of risks, uncertainties, and other factors that could
cause actual results to differ materially from those expressed in
any such forward-looking statements. These factors include, but are
not limited to those set forth in our most recently filed annual
report on Form 10-KSB and quarterly report on Form 10-Q, and other
factors detailed from time to time in filings with the Securities
and Exchange Commission. We expressly disclaim any responsibility
to update forward-looking statements.
Contact: ONI BioPharma Inc. Stanley B. Stein 386-418-4018 X222
www.oragenics.com
Oragenics (AMEX:ONI)
Historical Stock Chart
From Sep 2024 to Oct 2024
Oragenics (AMEX:ONI)
Historical Stock Chart
From Oct 2023 to Oct 2024